1
Abraham J Domb: Lipsopheres for controlled delivery of substances. Nova Pharmaceutical Corporation, Kilpatrick & Cody, February 23, 1993: US05188837 (236 worldwide citation)

A microsuspension system and method for its preparation is disclosed. The microsuspension contain lipospheres, which are solid, water-insoluble microparticles that have a layer of a phospholipid embedded on their surface. The core of the liposphere is a solid substance to be delivered, or a substanc ...


2
Ronald M Burch: Interleukin receptor expression inhibiting antisense oligonucleotides. Nova Pharmaceutical Corporation, Vincent L Fabiano, August 4, 1992: US05135917 (101 worldwide citation)

Disclosed are oligonucleotide compounds that inhibit interleukin receptor expression when administered to a human subject. Also disclosed are pharmaceutical compositions and methods for inhibiting human interleukin receptor expression.


3
Waclaw J Rzeszotarski, Babu J Mavunkel: Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists. Nova Pharmaceutical Corporation, Breneman & Georges, December 26, 1989: US04889860 (82 worldwide citation)

A potent, selective opioid receptor agonist or antagonist exhibiting properties useful for a longacting analgesic or opiate abuse treatment agent or appetite suppressant having the general formula: ##STR1## wherein R is methyl, cyclopropylmethyl or allyl, and R.sub.1 is an unsubstituted or substitut ...


4
Eyal Ron, Mark Chasin, Tom Turek, Robert S Langer: Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone. Massachusetts Institute of Technology, Nova Pharmaceutical Corporation, Kilpatrick & Cody, June 16, 1992: US05122367 (73 worldwide citation)

A controlled release device for the administration of biologically active growth hormone proteins or peptide fragments, and method of preparation thereof, wherein biologically active growth hormone is stabilized and release rate modulated by incorporation of a stabilizing compound. The controlled re ...


5
Waclaw J Rzeszotarski, Babu J Mavunkel: Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists. Nova Pharmaceutical Corporation, Breneman & Georges, July 26, 1988: US04760069 (73 worldwide citation)

A potent, selective opioid receptor agonist or antagonist exhibiting properties useful for a long-acting analgesic or opiate abuse treatment agent or appetite suppressant having the general formula: ##STR1## wherein R is methyl, cyclopropylmethyl or allyl, and R.sub.1 is an unsubstituted or substitu ...


6
Mary E Abreu, Waclaw Rzeszotarski, Donald J Kyle, Roger N Hiner, Richard L Elliott: Corticotropin-releasing factor antagonism compounds. Nova Pharmaceutical Corporation, Vincent L Fabiano, November 5, 1991: US05063245 (62 worldwide citation)

The present invention relates to a method of producing corticotropin-releasing factor (CRF) antagonist activity and thus provides a method of treating a wide range of stress-related disorders, including affective illnesses, such as depression and anxiety, as well as irritable bowel syndrome, anorexi ...


7
Abraham J Domb, Manoj Maniar: Liposphere delivery systems for local anesthetics. Nova Pharmaceutical Corporation, Kilpatrick & Cody, July 13, 1993: US05227165 (52 worldwide citation)

A local anesthetic microsuspension system is disclosed that includes lipospheres, that are solid, water-insoluble microparticles that have a layer of a phospholipid embedded on their surface. The core of the liposphere is a solid anesthetic such as lidocaine or marcaine, or an anesthetic dispersed i ...


8
Waclaw J Rzeszotarski, Robert L Hudkins, Maria E Guzewska: Antagonists of specific excitatory amino acid neurotransmitter receptors. Nova Pharmaceutical Corporation, Breneman Georges Hellwege & Yee, April 14, 1987: US04657899 (52 worldwide citation)

The invention pertains to novel, potent anticonvulsants, analgesics and cognition enhancers achieving their action through the antagonism of specific excitatory amino acid neurotransmitter receptors. In particular, the invention is directed to .omega.-[2-phosphonoalkyleneyl)phenyl]-2-aminoalkanoic a ...


9
Abraham J Domb: Biodegradable polymer compositions. Nova Pharmaceutical Corporation, Cushman Darby & Cushman, March 12, 1991: US04999417 (47 worldwide citation)

Biodegradable polyanhydrides or polyester compositions based on amino acids. The compositions may be used as carriers for drugs or the like or as the drug source itself. The polymers are prepared from amino acids which are modified to include an additional carboxylic acid group.


10
Abraham J Domb: Aromatic polyanhydride compositions. Nova Pharmaceutical Corporation, Kilpatrick & Cody, March 5, 1991: US04997904 (38 worldwide citation)

Aromatic anhydride copolymers containing at least two aromatic diacid units, which are soluble in chloroform or dichloromethane to concentrations between approximately 0.5 to 50% weight/volume, melt at temperatures below 180.degree. C., and have low crystallinity are disclosed. The copolymers may co ...



Click the thumbnails below to visualize the patent trend.